Materials for oral delivery of proteins and peptides
Source abstract
Abstract
Throughout history, oral administration has been regarded as the most convenient mode of drug delivery, as it requires minimal expertise and invasiveness. Although oral delivery works well for small-molecule drugs, oral delivery of macromolecules (particularly proteins and peptides) has been limited by acidic conditions in the stomach and low permeability across the intestinal epithelium. Accordingly, the large numbers of biologic drugs that have become available in the past 10 years typically require administration by injection or infusion. As such, a renewed emphasis has been placed on the development of novel materials that overcome the physiological challenges of oral delivery for macromolecular agents. This Review provides an overview of physiological barriers to the oral delivery of biologics and highlights the advances made in materials across various length scales, from small molecules to macroscopic devices. This Review also describes the current status of materials for oral delivery of protein and peptide drugs. New materials, beyond those that have already obtained regulatory approval, are needed to improve the bioavailability of orally administered proteins. In this Review, barriers to the oral delivery of protein-based therapies are discussed, along with the current translational landscape and state of the art of materials for oral protein delivery.
Source: openaire · Quality: candidate unverified · Source record ↗
Research context
OpenAlex topics: Advanced Drug Delivery Systems · Drug Solubulity and Delivery Systems · RNA Interference and Gene Delivery
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (100+)
Show source-provided references
1. US Food and Drug Administration. Novel drug approvals for 2018. FDA https://www.fda.gov/drugs/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products/novel-drug-approvals-2018 (2018).
2. Toutain, P. L. & Bousquet-Mélou, A. Bioavailability and its assessment. J. Vet. Pharmacol. Ther. 27, 455–466 (2004).10.1111/j.1365-2885.2004.00604.x ↗
3. Bardal, S. K., Waechter, J. E. & Martin, D. S. Applied Pharmacology 17–34 (Elsevier Saunders, 2011).10.1016/B978-1-4377-0310-8.00002-6 ↗
4. Shone, A., Burnside, J., Chipchase, S., Game, F. & Jeffcoate, W. Probing the validity of the probe-to-bone test in the diagnosis of osteomyelitis of the foot in diabetes. Diabetes Care 29, 945 (2006).10.2337/diacare.29.04.06.dc05-2450 ↗
5. Thomaidou, E. & Ramot, Y. Injection site reactions with the use of biological agents. Dermatol. Ther. 32, e12817 (2019).10.1111/dth.12817 ↗
6. Hilhorst, N., Spanoudi-Kitrimi, I., Goemans, N. & Morren, M. A. Injection site reactions after long-term subcutaneous delivery of drisapersen: a retrospective study. Eur. J. Pediatr. 178, 253–258 (2018).10.1007/s00431-018-3272-1 ↗
7. Messer, L. H., Berget, C., Beatson, C., Polsky, S. & Forlenza, G. P. Preserving skin integrity with chronic device use in diabetes. Diabetes Technol. Ther. 20, S254–S264 (2018).10.1089/dia.2018.0080 ↗
8. Richardson, T. & Kerr, D. Skin-related complications of insulin therapy: epidemiology and emerging management strategies. Am. J. Clin. Dermatol. 4, 661–667 (2003).10.2165/00128071-200304100-00001 ↗
9. Kerbleski, J. F. & Gottlieb, A. B. Dermatological complications and safety of anti-TNF treatments. Gut 58, 1033–1039 (2009).10.1136/gut.2008.163683 ↗
10. Liu, N. F. et al. Stigma in people with type 1 or type 2 diabetes. Clin. Diabetes 35, 27–34 (2017).10.2337/cd16-0020 ↗
11. Spain, C. V., Wright, J. J., Hahn, R. M., Wivel, A. & Martin, A. A. Self-reported barriers to adherence and persistence to treatment with injectable medications for type 2 diabetes. Clin. Ther. 38, 1653–1664.e1 (2016).10.1016/j.clinthera.2016.05.009 ↗
12. Crawford, A., Jewell, S., Mara, H., McCatty, L. & Pelfrey, R. Managing treatment fatigue in patients with multiple sclerosis on long-term therapy: the role of multiple sclerosis nurses. Patient Prefer. Adherence 8, 1093–1099 (2014).
13. Zhong, W. et al. Age and sex patterns of drug prescribing in a defined American population. Mayo Clin. Proc. 88, 697–707 (2013).10.1016/j.mayocp.2013.04.021 ↗
14. Zelikin, A. N., Ehrhardt, C. & Healy, A. M. Materials and methods for delivery of biological drugs. Nat. Chem. 8, 997–1007 (2016).10.1038/nchem.2629 ↗
15. Antosova, Z., Mackova, M., Kral, V. & Macek, T. Therapeutic application of peptides and proteins: parenteral forever? Trends Biotechnol. 27, 628–635 (2009).10.1016/j.tibtech.2009.07.009 ↗
16. Roger, E., Lagarce, F., Garcion, E. & Benoit, J. P. Biopharmaceutical parameters to consider in order to alter the fate of nanocarriers after oral delivery. Nanomedicine 5, 287–306 (2010).10.2217/nnm.09.110 ↗
17. Zhou, X. H. & Po, A. L. W. Peptide and protein drugs: II. Non-parenteral routes of delivery. Int. J. Pharm. 75, 117–130 (1991).10.1016/0378-5173(91)90185-Q ↗
18. Fjellestad-Paulsen, A., Hoglund, P., Lundin, S. & Paulsen, O. Pharmacokinetics of 1-deamino-8-D-arginine vasopressin after various routes of administration in healthy volunteers. Clin. Endocrinol. 38, 177–182 (1993). Reports the oral bioavailability (0.1%) of one of the first oral formulations of the synthetic hormone desmopressin.10.1111/j.1365-2265.1993.tb00990.x ↗
19. Fábián, T. K., Hermann, P., Beck, A., Fejérdy, P. & Fábián, G. Salivary defense proteins: their network and role in innate and acquired oral immunity. Int. J. Mol. Sci. 13, 4295–4320 (2012).10.3390/ijms13044295 ↗
20. Allen, A. & Carroll, N. J. Adherent and soluble mucus in the stomach and duodenum. Dig. Dis. Sci. 30, 55S–62S (1985).10.1007/BF01309386 ↗
21. Allen, A., Flemstrom, G., Garner, A. & Kivilaakso, E. Gastroduodenal mucosal protection. Physiol. Rev. 73, 823–857 (1993).10.1152/physrev.1993.73.4.823 ↗
22. Whitcomb, D. C. & Lowe, M. E. Human pancreatic digestive enzymes. Dig. Dis. Sci. 52, 1–17 (2007).10.1007/s10620-006-9589-z ↗
23. Masaoka, Y., Tanaka, Y., Kataoka, M., Sakuma, S. & Yamashita, S. Site of drug absorption after oral administration: assessment of membrane permeability and luminal concentration of drugs in each segment of gastrointestinal tract. Eur. J. Pharm. Sci. 29, 240–250 (2006).10.1016/j.ejps.2006.06.004 ↗
24. Kararli, T. T. Comparison of the gastrointestinal anatomy, physiology, and biochemistry of humans and commonly used laboratory animals. Biopharm. Drug Dispos. 16, 351–380 (1995).10.1002/bdd.2510160502 ↗
25. Daugherty, A. L. & Mrsny, R. J. Transcellular uptake mechanisms of the intestinal epithelial barrier Part one. Pharm. Sci. Technol. Today 2, 144–151 (1999).10.1016/S1461-5347(99)00142-X ↗
26. Golub, A. L., Frost, R. W., Betlach, C. J. & Gonzalez, M. A. Physiologic considerations in drug absorption from the gastrointestinal tract. J. Allergy Clin. Immunol. 78, 689–694 (1986).10.1016/0091-6749(86)90047-3 ↗
27. Perez-Vilar, J. & Hill, R. L. The structure and assembly of secreted mucins. J. Biol. Chem. 274, 31751–31754 (1999).10.1074/jbc.274.45.31751 ↗
28. Murgia, X., Loretz, B., Hartwig, O., Hittinger, M. & Lehr, C. M. The role of mucus on drug transport and its potential to affect therapeutic outcomes. Adv. Drug Deliv. Rev. 124, 82–97 (2018).10.1016/j.addr.2017.10.009 ↗
29. Ensign, L. M., Cone, R. & Hanes, J. Oral drug delivery with polymeric nanoparticles: the gastrointestinal mucus barriers. Adv. Drug Deliv. Rev. 64, 557–570 (2012). Outlines key features of the mucus barriers that can impede oral delivery.10.1016/j.addr.2011.12.009 ↗
30. Lai, S. K., Wang, Y. Y. & Hanes, J. Mucus-penetrating nanoparticles for drug and gene delivery to mucosal tissues. Adv. Drug Deliv. Rev. 61, 158–171 (2009).10.1016/j.addr.2008.11.002 ↗
31. Yildiz, H. M., McKelvey, C. A., Marsac, P. J. & Carrier, R. L. Size selectivity of intestinal mucus to diffusing particulates is dependent on surface chemistry and exposure to lipids. J. Drug Target. 23, 768–774 (2015).10.3109/1061186X.2015.1086359 ↗
32. Maisel, K., Ensign, L., Reddy, M., Cone, R. & Hanes, J. Effect of surface chemistry on nanoparticle interaction with gastrointestinal mucus and distribution in the gastrointestinal tract following oral and rectal administration in the mouse. J. Control. Release 197, 48–57 (2015).10.1016/j.jconrel.2014.10.026 ↗
33. Carlson, T. L., Lock, J. Y. & Carrier, R. L. Engineering the mucus barrier. Annu. Rev. Biomed. Eng. 20, 197–220 (2018).10.1146/annurev-bioeng-062117-121156 ↗
34. Ducheˇne, D., Touchard, F. & Peppas, N. A. Pharmaceutical and medical aspects of bioadhesive systems for drug administration. Drug Dev. Ind. Pharm. 14, 283–318 (1988).10.3109/03639048809151972 ↗
35. Ch’Ng, H. S., Park, H., Kelly, P. & Robinson, J. R. Bioadhesive polymers as platforms for oral controlled drug delivery II: synthesis and evaluation of some swelling, water-insoluble bioadhesive polymers. J. Pharm. Sci. 74, 399–405 (1985).10.1002/jps.2600740407 ↗
36. Pullan, R. D. et al. Thickness of adherent mucus gel on colonic mucosa in humans and its relevance to colitis. Gut 35, 353–359 (1994).10.1136/gut.35.3.353 ↗
37. Elderman, M. et al. The effect of age on the intestinal mucus thickness, microbiota composition and immunity in relation to sex in mice. PLOS One 12, e0184274 (2017).10.1371/journal.pone.0184274 ↗
38. Bahari, H. M., Ross, I. N. & Turnberg, L. A. Demonstration of a pH gradient across the mucus layer on the surface of human gastric mucosa in vitro. Gut 23, 513–516 (1982).10.1136/gut.23.6.513 ↗
39. Mayhew, T. M., Myklebust, R., Whybrow, A. & Jenkins, R. Epithelial integrity, cell death and cell loss in mammalian small intestine. Histol. Histopathol. 14, 257–267 (1999).
40. Middleton, C. Crypts, villi and microvilli in the small intestine of the rat. A stereological study of their variability within and between animals. J. Anat. 141, 1–17 (1985).
41. Salim, S. Y. & Söderholm, J. D. Importance of disrupted intestinal barrier in inflammatory bowel diseases. Inflamm. Bowel Dis. 17, 362–381 (2011).10.1002/ibd.21403 ↗
42. Allaire, J. M. et al. The intestinal epithelium: central coordinator of mucosal immunity. Trends Immunol. 39, 677–696 (2018). Provides a thorough overview of the intestinal epithelium and surrounding environment.10.1016/j.it.2018.04.002 ↗
43. Mace, O. J., Tehan, B. & Marshall, F. Pharmacology and physiology of gastrointestinal enteroendocrine cells. Pharmacol. Res. Perspect. 3, e00155 (2015).
44. Denker, B. M. & Nigam, S. K. Molecular structure and assembly of the tight junction. Am. J. Physiol. 274, F1–F9 (1998).10.1152/ajpcell.1998.274.1.C1 ↗
45. Fine, K. D., Santa Ana, C. A., Porter, J. L. & Fordtran, J. S. Effect of changing intestinal flow rate on a measurement of intestinal permeability. Gastroenterology 108, 983–989 (1995).10.1016/0016-5085(95)90193-0 ↗
46. Linnankoski, J. et al. Paracellular porosity and pore size of the human intestinal epithelium in tissue and cell culture models. J. Pharm. Sci. 99, 2166–2175 (2010).10.1002/jps.21961 ↗
47. Turner, J. R. Intestinal mucosal barrier function in health and disease. Nat. Rev. Immunol. 9, 799–809 (2009).10.1038/nri2653 ↗
48. Amin, M. L. P-glycoprotein inhibition for optimal drug delivery. Drug Target Insights 7, 27–34 (2013).
49. Sjöstedt, N., Holvikari, K., Tammela, P. & Kidron, H. Inhibition of breast cancer resistance protein and multidrug resistance associated protein 2 by natural compounds and their derivatives. Mol. Pharm. 14, 135–146 (2017).10.1021/acs.molpharmaceut.6b00754 ↗
50. Lea, T. in The Impact of Food Bioactives on Health: In Vitro and Ex Vivo Models (eds Verhoeckx, K. et al.) 95–102 (Springer International, 2015).10.1007/978-3-319-16104-4_9 ↗
51. Karasov, W. H. Integrative physiology of transcellular and paracellular intestinal absorption. J. Exp. Biol. 220, 2495–2501(2017).10.1242/jeb.144048 ↗
52. Pereira de Sousa, I. & Bernkop-Schnürch, A. Pre-systemic metabolism of orally administered drugs and strategies to overcome it. J. Control. Release 192, 301–309 (2014).10.1016/j.jconrel.2014.08.004 ↗
53. Goldberg, M. & Gomez-Orellana, I. Challenges for the oral delivery of macromolecules. Nat. Rev. Drug Discov. 2, 289–295 (2003).10.1038/nrd1067 ↗
54. Bittner, B. et al. Erratum: development of a subcutaneous formulation for trastuzumab — nonclinical and clinical bridging approach to the approved intravenous dosing regimen. Drug Res 63, 602 (2013).10.1055/s-0033-1357211 ↗
55. Pivot, X. et al. Preference for subcutaneous or intravenous administration of trastuzumab in patients with HER2-positive early breast cancer (PrefHer): an open-label randomised study. Lancet Oncol. 14, 962–970 (2013).10.1016/S1470-2045(13)70383-8 ↗
56. Hourcade-Potelleret, F. et al. Use of a population pharmacokinetic approach for the clinical development of a fixed-dose subcutaneous formulation of trastuzumab. CPT Pharmacometrics Syst. Pharmacol. 3, e87 (2014).10.1038/psp.2013.63 ↗
57. Shah, R. B., Patel, M., Maahs, D. M. & Shah, V. N. Insulin delivery methods: Past, present and future. Int. J. Pharm. Investig. 6, 1–9 (2016). Outlines key ways in which insulin has been attempted to be delivered throughout history.10.4103/2230-973X.176456 ↗
58. US Food and Drug Administration. FDA approves first oral GLP-1 treatment for type 2 diabetes. FDA https://www.fda.gov/news-events/press-announcements/fda-approves-first-oral-glp-1-treatment-type-2-diabetes (2019). This is the first FDA-approved oral biologic for type 2 diabetes mellitus.
59. Winstanley, P. A. & Orme, M. L. The effects of food on drug bioavailability. Br. J. Clin. Pharmacol. 28, 621–628 (1989).10.1111/j.1365-2125.1989.tb03554.x ↗
60. Melander, A. Influence of food on the bioavailability of drugs. Clin. Pharmacokinet. 3, 337–351 (1978).10.2165/00003088-197803050-00001 ↗
61. Karsdal, M. A. et al. Influence of food intake on the bioavailability and efficacy of oral calcitonin. Br. J. Clin. Pharmacol. 67, 413–420 (2009).10.1111/j.1365-2125.2009.03371.x ↗
62. Yasuji, T., Kondo, H. & Sako, K. The effect of food on the oral bioavailability of drugs: a review of current developments and pharmaceutical technologies for pharmacokinetic control. Ther. Deliv. 3, 81–90 (2012).10.4155/tde.11.142 ↗
63. Hoppu, K. Prehepatic metabolism of drugs — a mechanism for low and variable oral bioavailability. Pediatr. Nephrol. 13, 85–89 (1999).10.1007/s004670050569 ↗
64. Agrawal, S. & Panchagnula, R. Implication of biopharmaceutics and pharmacokinetics of rifampicin in variable bioavailability from solid oral dosage form. Biopharm. Drug Dispos. 26, 321–334 (2005).10.1002/bdd.464 ↗
65. El-Kattan, A. & Varma, M. in Topics on Drug Metabolism Ch. 1 (ed Paxton, J.) (IntechOpen, 2012).
66. Lamson, N. L., Berger, A., Fein, K. C., & Whitehead, K. A. Anionic nanoparticles enable the oral delivery of proteins by enhancing intestinal permeability. Nat. Biomed. Eng. https://doi.org/10.1038/s41551-019-0465-5 (2019).10.1038/s41551-019-0465-5 ↗
67. Bernkop-Schnürch, A. The use of inhibitory agents to overcome the enzymatic barrier to perorally administered therapeutic peptides and proteins. J. Control. Release 52, 1–16 (1998).10.1016/S0168-3659(97)00204-6 ↗
68. Bernkop-Schnürch, A. & Marschütz, M. K. Development and in vitro evaluation of systems to protect peptide drugs from aminopeptidase N. Pharm. Res. 14, 181–185 (1997).10.1023/A:1012096510125 ↗
69. Hastewell, J., Antonin, K. H., Fox, R. & Mackay, M. The colonic absorption of human calcitonin: the effects of increasing local concentration and co-administration with a protease inhibitor. Int. J. Pharm. 126, 245–251 (1995).10.1016/0378-5173(95)04134-6 ↗
70. Yamamoto, A. et al. Effects of various protease inhibitors on the intestinal absorption and degradation of insulin in rats. Pharm. Res. 11, 1496–1500 (1994).10.1023/A:1018968611962 ↗
71. Otsuki, M., Ohki, A., Okabayashi, Y., Suehiro, I. & Baba, S. Effect of synthetic protease inhibitor camostate on pancreatic exocrine function in rats. Pancreas 2, 164–169 (1987).10.1097/00006676-198703000-00007 ↗
72. Melmed, R. N., El-Aaser, A. A. A. & Holt, S. J. Hypertrophy and hyperplasia of the neonatal rat exocrine pancreas induced by orally administered soybean trypsin inhibitor. Biochim. Biophys. Acta 421, 280–288 (1976).10.1016/0304-4165(76)90294-4 ↗
73. Kunin, C. M. Nephrotoxicity of antibiotics. JAMA 202, 204–208 (1967).10.1001/jama.1967.03130160078015 ↗
74. Friess, H., Kleeff, J., Isenmann, R., Malfertheiner, P. & Büchler, M. W. Adaptation of the human pancreas to inhibition of luminal proteolytic activity. Gastroenterology 115, 388–396 (1998).10.1016/S0016-5085(98)70205-7 ↗
75. Binkley, N. et al. A phase 3 trial of the efficacy and safety of oral recombinant calcitonin: the Oral Calcitonin in Postmenopausal Osteoporosis (ORACAL) trial. J. Bone Miner. Res. 27, 1821–1829 (2012).10.1002/jbmr.1602 ↗
76. Tomita, M., Hayashi, M. & Awazu, S. Absorption-enhancing mechanism of EDTA, caprate, and decanoylcarnitine in Caco-2 cells. J. Pharm. Sci. 85, 608–611 (1996).10.1021/js9504604 ↗
77. Welling, S. H. et al. The role of citric acid in oral peptide and protein formulations: relationship between calcium chelation and proteolysis inhibition. Eur. J. Pharm. Biopharm. 86, 544–551 (2014).10.1016/j.ejpb.2013.12.017 ↗
78. Bolourchian, N. & Dadashzadeh, S. pH-independent release of propranolol hydrochloride from HPMC-based matrices using organic acids. Daru 16, 136–142 (2008).
79. Dvorˇácˇková, K. et al. The effect of acid pH modifiers on the release characteristics of weakly basic drug from hydrophlilic–lipophilic matrices. AAPS PharmSciTech 14, 1341–1348 (2013).10.1208/s12249-013-0019-1 ↗
80. Noach, A. B. J., Kurosaki, Y., Blom-Roosemalen, M. C. M., de Boer, A. G. & Breimer, D. D. Cell-polarity dependent effect of chelation on the paracellular permeability of confluent Caco-2 cell monolayers. Int. J. Pharm. 90, 229–237 (1993).10.1016/0378-5173(93)90195-L ↗
81. Shen, L., Zhao, H. Y., Du, J. & Wang, F. Anti-tumor activities of four chelating agents against human neuroblastoma cells. In Vivo 19, 233–236 (2005).
82. Collares-Buzato, C. B., McEwan, G. T. A., Jepson, M. A., Simmons, N. L. & Hirst, B. H. Paracellular barrier and junctional protein distribution depend on basolateral extracellular Ca2+ in cultured epithelia. Biochim. Biophys. Acta 1222, 147–158 (1994).10.1016/0167-4889(94)90163-5 ↗
83. Lueßen, H. L. et al. Mucoadhesive polymers in peroral peptide drug delivery. I. Influence of mucoadhesive excipients on the proteolytic activity of intestinal enzymes. Eur. J. Pharm. Sci. 4, 117–128 (1996).10.1016/0928-0987(95)00042-9 ↗
84. Lindahl, A., Ungell, A.-L., Knutson, L. & Lennernäs, H. Characterization of fluids from the stomach and proximal jejunum in men and women. Pharm. Res. 14, 497–502 (1997).10.1023/A:1012107801889 ↗
85. Bernkop-Schnürch, A. & Krajicek, M. E. Mucoadhesive polymers as platforms for peroral peptide delivery and absorption: synthesis and evaluation of different chitosan-EDTA conjugates. J. Control. Release 50, 215–223 (1998).10.1016/S0168-3659(97)00136-3 ↗
86. Lannigan, R. S. & Yamarik, T. A. Final report on the safety assessment of EDTA, calcium disodium EDTA, diammonium EDTA, dipotassium EDTA, disodium EDTA, TEA-EDTA, tetrasodium EDTA, tripotassium EDTA, trisodium EDTA, HEDTA and trisodium HEDTA. Int. J. Toxicol. 21, 95–142 (2002).10.1080/10915810290096522 ↗
87. Ilbäck, N. G., Stålhandske, T. & Lindh, U. Effects of EDTA on trace elements and cardiovascular function in the anesthetised rabbit. Biol. Trace Elem. Res. 76, 133–148 (2000).10.1385/BTER:76:2:133 ↗
88. Lee, H. J., McAuley, A., Schilke, K. F. & McGuire, J. Molecular origins of surfactant-mediated stabilization of protein drugs. Adv. Drug Deliv. Rev. 63, 1160–1171 (2011).10.1016/j.addr.2011.06.015 ↗
89. Jones, L. S., Bam, N. B. & Randolph, T. W. in Therapeutic Protein and Peptide Formulation and Delivery Ch. 12 (eds Shahrokh, Z., Sluzky, V., Cleland, J. L., Shire, S. J. & Randolph, T. W.) 206–222 (American Chemical Society, 1997).
90. Shao, Z., Li, Y., Krishnamoorthy, R., Chermak, T. & Mitra, A. K. Differential effects of anionic, cationic, nonionic, and physiologic surfactants on the dissociation, α-chymotryptic degradation, and enteral absorption of insulin hexamers. Pharm. Res. 10, 243–251 (1993).10.1023/A:1018990928259 ↗
91. Gupta, S., Kesarla, R. & Omri, A. Formulation strategies to improve the bioavailability of poorly absorbed drugs with special emphasis on self-emulsifying systems. ISRN Pharm. 2013, 848043 (2013).
92. Dahlgren, D. et al. Effect of absorption-modifying excipients, hypotonicity, and enteric neural activity in an in vivo model for small intestinal transport. Int. J. Pharm. 549, 239–248 (2018).10.1016/j.ijpharm.2018.07.057 ↗
93. Elsayed, A. et al. Chitosan–sodium lauryl sulfate nanoparticles as a carrier system for the in vivo delivery of oral insulin. AAPS PharmSciTech 12, 958–964 (2011).10.1208/s12249-011-9647-5 ↗
94. Lo, Y. L. Relationships between the hydrophilic–lipophilic balance values of pharmaceutical excipients and their multidrug resistance modulating effect in Caco-2 cells and rat intestines. J. Control. Release 90, 37–48 (2003).10.1016/S0168-3659(03)00163-9 ↗
95. Sugibayashi, K., Onuki, Y. & Takayama, K. Displacement of tight junction proteins from detergent-resistant membrane domains by treatment with sodium caprate. Eur. J. Pharm. Sci. 36, 246–253 (2009).10.1016/j.ejps.2008.09.011 ↗
96. Kurasawa, M. et al. Regulation of tight junction permeability by sodium caprate in human keratinocytes and reconstructed epidermis. Biochem. Biophys. Res. Commun. 381, 171–175 (2009).10.1016/j.bbrc.2009.02.005 ↗
97. Maher, S., Leonard, T. W., Jacobsen, J. & Brayden, D. J. Safety and efficacy of sodium caprate in promoting oral drug absorption: from in vitro to the clinic. Adv. Drug Deliv. Rev. 61, 1427–1449 (2009).10.1016/j.addr.2009.09.006 ↗
98. Heade, J., Maher, S., Bleiel, S. B. & Brayden, D. J. Labrasol and salts of medium-chain fatty acids can be combined in low concentrations to increase the permeability of a macromolecule marker across isolated rat intestinal mucosae. J. Pharm. Sci. 107, 1648–1655 (2018).10.1016/j.xphs.2018.02.012 ↗
99. Keown, A. Merrion Pharma looks to wind up operations, announces liquidation plans. BioSpace https://www.biospace.com/article/merrion-pharma-looks-to-wind-up-operations-announces-liquidation-plans-/ (2016).
100. Leonard, T. W., Lynch, J., McKenna, M. J. & Brayden, D. J. Promoting absorption of drugs in humans using medium-chain fatty acid-based solid dosage forms: GIPET. Expert Opin. Drug Deliv. 3, 685–692 (2006).10.1517/17425247.3.5.685 ↗